Bruce Cleveland on Crossing Medtech's Traction Gap

Key Takeaways

• Bruce Cleveland coined the traction gap framework to describe the structural no-man's-land between initial product release and repeatable commercial traction in venture-backed companies.

• The traction gap is not a sales problem and not a capital problem. It's a market architecture problem. Hiring more reps before solving it makes it worse.

• The first prerequisite for crossing the traction gap: minimum viable category. Buyers and clinicians must be able to describe your problem definition without prompting from your team.

• The second prerequisite: process repeatability. Someone other than the founder closes deals consistently, on a predictable cadence, without escalation.

• On episode 278 of The State of MedTech, Bruce Cleveland connected the traction gap directly to market-product fit, the concept that must precede any repeatable commercial motion in medtech.

You have FDA clearance. You have clinical data. Your physician champions love the device. And the board wants traction numbers.

This is not a sales problem.

Bruce Cleveland, Founding Partner at Wildcat Venture Partners and author of Traversing the Traction Gap, has a name for what you're experiencing. Understanding that name changes how you diagnose the problem, allocate resources, and survive the next 18 months.

Watch the full episode on YouTube

What Bruce Cleveland's Traction Gap Framework Means for Medtech

I've spent 370+ episodes on The State of MedTech talking with founders, operators, and investors about why medtech companies stall after clinical validation.

One of the clearest frameworks I've encountered comes from Bruce Cleveland, whom I interviewed on episode 278. Cleveland maps the startup journey from left to right: structured product engineering on one end, scaled commercial operations on the other.

In the middle sits the traction gap.

I broke down this framework on a recent solo episode about market engineering for medtech startups:

The traction gap is a space between building a product and achieving real, repeatable traction.

The word "repeatable" is doing heavy lifting in that definition. Founders often measure traction in revenue. Cleveland defines it more precisely.

Traction is not your first three accounts or a strong NSM pipeline. Traction is when someone other than the founding team closes a deal, on schedule, without the founder personally handling every objection.

If you can't say yes to that, you're still in the gap.

And the common failure mode? Founders feel it as a capital problem. Boards read it as sales execution. Companies raise more money and hire more reps.

But the gap is structural. You can't hire through it.

I covered this exact failure pattern on that same market engineering episode:

The most common thing I see in MedTech is a solution without a market.

That captures the traction gap failure mode precisely. A strong product, early clinical wins, no defined category. The market doesn't know how to evaluate you.

So it compares you to the nearest incumbent. That's not a budget problem. That's a market architecture failure.

How the Traction Gap in Medtech Differs From Crossing the Chasm

Most founders I talk with know Geoffrey Moore's Crossing the Chasm. So let me be precise about where these two frameworks intersect.

They're sequential, not competing.

You need to cross the traction gap before you're in a position to approach the chasm at all.

On the chasm side, the question is how to move pragmatist buyers into mainstream adoption. On the traction gap side, the question is whether you have a repeatable proof of concept to stand on.

I covered the psychological gap between these two buyer groups on an episode about technology adoption and how medtech startups cross the chasm:

The early market are vision-driven, they buy possibility. The early majority is pragmatic, they buy proven outcomes.

The traction gap lives entirely inside the early market. Your job isn't to convert pragmatists yet. Your job is to prove repeatability with the believers so you have a credible case for the pragmatists later.

This is where conflating the two frameworks gets expensive. Founders who treat a traction gap problem as a chasm problem apply chasm tactics: vertical focus, bowling alley strategies, whole product thinking. They discover the real problem was upstream the whole time.

Why Minimum Viable Category Comes Before Any Commercial Motion in Medtech

There are two prerequisites for crossing the traction gap. The first is minimum viable category.

The category defines how your product gets evaluated. It sets the rules of the comparison before the first sales conversation happens.

On that market engineering episode, I put it directly:

The category really defines how your product is evaluated. It's essentially setting the rules to the game.

When you don't own a clear category, the market does that work for you. And it rarely categorizes you favorably.

You get compared to incumbents you don't resemble. You get placed in competitive frames you didn't choose. And you get commoditized before you've established what makes you different.

What does minimum viable category look like in practice?

The test is concrete. When clinicians and buyers who haven't been coached by your team start describing the problem your way, using the language you established, you're there.

Traction starts first when people in your market start using your language. It's when clinicians start describing the problem your way and then the buyer starts framing decisions using the category that you're developing.

I've seen this shift happen in the field. When clinical reps start getting pulled into conversations by the clinician instead of pushing to get in the door, something has changed.

The category is taking hold.

Most companies I work with haven't reached this before they hire their first commercial team. They get through FDA, they assume the market will route itself correctly.

It won't.

The market needs to understand what game it's playing before buyers can evaluate you fairly. That's what category design is for. And it has to happen before the first rep hits the street.

Read more about category design in medtech and how it precedes commercial traction.

Why Process Repeatability Is the Second Gate Before Commercial Scale

Minimum viable category gets you to the starting line. Process repeatability is what gets you across.

Founders often treat a sales playbook as a proxy for process repeatability. A sales playbook is a document. Process repeatability is an observable outcome.

The test: can someone other than the founder close a deal, on a predictable cadence, without needing founder involvement to resolve objections?

If the answer is no, the traction gap is still open.

I've watched this play out across dozens of medtech companies. A founder who came up through clinical sales at a Mazor or Stryker, who knows the VAC process from the inside, who can handle a GPO objection in real time. That person builds early traction through sheer domain competence.

But that's not a sales process. That's a founder personally carrying deals.

When that founder hires two reps with similar backgrounds, the deals get harder. Sales cycles stretch. Forecasts miss. The board starts asking harder questions.

Because the process was never really a process. It was one person with deep contextual intelligence and a device.

The signal that you're approaching process repeatability isn't a playbook document. It's when a rep closes a deal and you're surprised it happened, because you weren't in the room.

What This Means for Medtech Founders

In my experience working with medtech founders, the traction gap is the most commonly misdiagnosed problem I encounter.

Founders feel it as a capital problem: more runway to reach the metrics that unlock the next round. Boards read it as a sales problem: a better VP of Sales, more reps, a stronger pitch. Someone in marketing argues awareness is the constraint.

Bruce Cleveland's framework is useful precisely because it reframes all of these as downstream symptoms. The structural cause is upstream.

Before you've established minimum viable category, more marketing produces more confused buyers. Before you've achieved process repeatability, more reps produce more unscalable founder dependency.

The companies that cross the traction gap do it in sequence: category first, then process, then headcount. Not the other way around.

I see this pattern in the calls I take at MarketCraft. The stalled founder story always has the same shape: clearance achieved, early wins closed, new hires underperforming. The sequence was wrong.

The traction gap doesn't close by doing more of what produced the early wins. It closes by building the market architecture underneath those wins so they become a foundation instead of a lucky streak.

For a deeper look at how this sequencing fits into a full commercialization plan, see the medtech commercialization strategy overview.

Frequently Asked Questions

What Is the Traction Gap in Medtech?

The traction gap in medtech is the structural gap between a company's initial product release and its first instance of real, repeatable commercial traction. Bruce Cleveland of Wildcat Venture Partners coined the framework in his book Traversing the Traction Gap.

Companies stuck in this gap typically have working products, early clinical adoption, and some revenue, but no predictable or scalable commercial process. FDA clearance is the starting line, not the finish line. Repeatability marks the end of the traction gap.

How Do Medtech Companies Cross the Traction Gap?

Medtech companies cross the traction gap by establishing two prerequisites before scaling headcount. First, minimum viable category: buyers and clinicians describe the problem your way without coaching from your team.

Second, process repeatability: a team member other than the founder closes deals on a predictable cadence without founder escalation. Adding sales reps before meeting both prerequisites extends the gap rather than closing it. Sequencing is the answer, not headcount.

What Does Bruce Cleveland Say About the Traction Gap in Medtech?

Bruce Cleveland argues that the traction gap is a structural problem, not a sales or capital problem. His book Traversing the Traction Gap and his work at Wildcat Venture Partners identify the gap between initial product release and commercial scale as the highest-risk period for startups.

Cleveland frames market-product fit as the prerequisite that must precede commercial scaling. You can't iterate your way into commercial traction without first building a category the market understands and can evaluate on its own terms.

What Is the Difference Between the Traction Gap and Crossing the Chasm in Medtech?

The traction gap and crossing the chasm are sequential frameworks, not competing ones. The traction gap, from Bruce Cleveland, describes the gap between initial product release and repeatable commercial traction.

Crossing the chasm, from Geoffrey Moore, describes the gap between early adopters and the pragmatist mainstream. In medtech, you must cross the traction gap first. Minimum viable category and process repeatability are prerequisites before bowling alley targeting or vertical focus strategies can have any effect.

Listen to Bruce Cleveland's Full Story

Bruce Cleveland's conversation with Omar Khateeb is available on The State of MedTech, episode 278. Watch on YouTube. Subscribe wherever you listen to podcasts.

About Bruce Cleveland

Bruce Cleveland is a Founding Partner at Wildcat Venture Partners and the author of Traversing the Traction Gap, the definitive framework for moving venture-backed startups from initial product release to commercial scale.

He was formerly an executive at Oracle and Siebel Systems and has worked with startups across technology and life sciences.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.